Related Experiment Video
Updated: May 12, 2026
09:07
Murine Model of Epicutaneously-Induced Immunomodulation
Published on: June 24, 2025
CD19 expression in B cells regulates atopic dermatitis in a mouse model.
Koichi Yanaba1, Masahiro Kamata, Yoshihide Asano
1Department of Dermatology, Faculty of Medicine, University of Tokyo, Tokyo, Japan. yanaba@jikei.ac.jp
The American Journal of Pathology
|April 16, 2013
Summary
CD19-deficient B cells reduce T cell proliferation and inflammatory responses in a mouse model of atopic dermatitis. This suggests B cell-targeted therapies may treat this skin condition.
Area of Science:
- Immunology
- Dermatology
- Cell Biology
Background:
- Atopic dermatitis is a chronic inflammatory skin disease with unclear B cell roles.
- Murine models are crucial for understanding atopic dermatitis pathogenesis.
- CD19 is a B cell surface marker implicated in immune regulation.
Purpose of the Study:
- To investigate the role of CD19-expressing B cells in a murine model of atopic dermatitis.
- To assess the impact of CD19 deficiency on allergic skin inflammation and T cell responses.
Main Methods:
- Utilized a murine model of atopic dermatitis induced by ovalbumin sensitization.
- Assessed allergic skin inflammation in CD19-deficient and wild-type mice.
- Analyzed T cell proliferation, cytokine secretion (IL-4, IL-13, IL-17), and immune cell infiltration.
Main Results:
- CD19 deficiency reduced eosinophil and CD4(+) T cell infiltration in skin lesions.
- Reduced epidermal and dermal thickening observed in CD19-deficient mice.
- CD19 deficiency impaired ovalbumin-induced CD4(+) T cell proliferation and decreased IL-4, IL-13, and IL-17 secretion.
Conclusions:
- CD19 on B cells is critical for antigen-specific CD4(+) T cell proliferation.
- B cell CD19 plays a significant role in T helper 2 and T helper 17 responses in atopic dermatitis.
- Targeting CD19(+) B cells may offer a therapeutic strategy for atopic dermatitis treatment.
